華魯恆升(600426.SH):酰胺及尼龍新材料項目(30萬噸/年)己內酰胺及配套裝置投產
格隆匯10月8日丨華魯恆升(600426.SH)公佈,公司酰胺及尼龍新材料項目(30萬噸/年)己內酰胺及配套裝置已打通流程,生產出合格產品,進入試生產階段。20萬噸尼龍6切片等生產裝置目前處於在建狀態,預計明年上半年投產。
己內酰胺及配套裝置達產後,可年產己內酰胺30萬噸、硫銨48萬噸,能夠進一步壯大公司化工新材料板塊,優化產品結構,提高企業盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.